
Optical Preclinical Imaging Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034)
Description
The global optical preclinical imaging market size was valued at USD 640.40 Million in 2024 , driven by rising technical advancements in optical imaging facilitating smooth drug development across the globe. The market is expected to grow at a CAGR of 5.00% during the forecast period of 2025-2034, with the values likely to rise from USD 1043.14 Million by 2034.
Optical Preclinical Imaging: Introduction
Preclinical imaging is an essential diagnostic and research tool used in drug development and discovery. Preclinical imaging includes micro-ultrasound, optical imaging, CT, PET, and MRIs, among others. Optical imaging is divided into bioluminescence and fluorescence. It is rapid, easy to perform, and is commonly used for molecular visualizations. It can prove to be highly effective for the pharmaceutical industry as it enables the prior analysis of drugs in pipeline, facilitating faster drug development.
Global Optical Preclinical Imaging Market Analysis
The sudden outbreak of COVID-19 and increasing prevalence of chronic diseases has expediated drug and vaccine development. With the ongoing trend of machine learning and artificial intelligence, the healthcare industry is witnessing the convergence of new technologies into medical ecosystem. This is has led to significant optical preclinical imaging market demand.
Animals are often used as the initial model for testing and determining the effects of a drug. However, collecting the data sets can be difficult, owing to their different sizes and physical positions. To solve this problem, InVivo analytics has developed a fast cloud-based data analysis platform called InVIvoAX. Imaging software like Harmony® and Columbus™ are being used for high content imaging, data storage and analysis.
The optical preclinical imaging market growth can also be accredited to the advent of new imaging technologies. Researchers have introduced imaging mass cytometry to analyze the detection of proteins within tissue sections with the help of heavy metal tagged antibodies. In September 2023, Revvity Inc., unveiled an enhanced imaging portfolio in preclinical research which includes IVIS® Spectrum 2 and the IVIS SpectrumCT 2 imaging systems, crafted to elevate the sensitivity standards in in vivo optical imaging.
To facilitate fast-tracking and rapid evaluation of therapeutic candidates, Revvity's QuantumTM GX3 microCT structural imaging solution has been enabled with increased resolution and speed for both in vivo and ex vivo imaging. Such product launches will add significant growth the optical preclinical imaging market value.
Global Optical Preclinical Imaging Market Segmentation
"Optical Preclinical Imaging Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:
Market Breakup by Modality
The United States is expected to lead the optical preclinical imaging market share with the implementation of the Inflation Reduction Act of 2022. This act emphasizes the reduction of device and drug prices in the country. This indicates that the traditional research and development methods will take a backseat as the pharma companies keenly adopt machine learning and artificial intelligence technology driven platforms to accelerate drug development. The integration has already been initiated and it is fairly smooth, owing to the presence of a robust healthcare infrastructure.
Europe has been one of the leading regions in the market as it is home to several academic institutions, pioneering research and development in numerous healthcare domains. Asia Pacific is also expected to witness the fastest growth attributed to rising medical infrastructure development. In addition, major healthcare companies have been making hefty investments in the region to leverage the easy availability of both economical and intellectual resources.
Global Optical Preclinical Imaging Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Optical Preclinical Imaging: Introduction
Preclinical imaging is an essential diagnostic and research tool used in drug development and discovery. Preclinical imaging includes micro-ultrasound, optical imaging, CT, PET, and MRIs, among others. Optical imaging is divided into bioluminescence and fluorescence. It is rapid, easy to perform, and is commonly used for molecular visualizations. It can prove to be highly effective for the pharmaceutical industry as it enables the prior analysis of drugs in pipeline, facilitating faster drug development.
Global Optical Preclinical Imaging Market Analysis
The sudden outbreak of COVID-19 and increasing prevalence of chronic diseases has expediated drug and vaccine development. With the ongoing trend of machine learning and artificial intelligence, the healthcare industry is witnessing the convergence of new technologies into medical ecosystem. This is has led to significant optical preclinical imaging market demand.
Animals are often used as the initial model for testing and determining the effects of a drug. However, collecting the data sets can be difficult, owing to their different sizes and physical positions. To solve this problem, InVivo analytics has developed a fast cloud-based data analysis platform called InVIvoAX. Imaging software like Harmony® and Columbus™ are being used for high content imaging, data storage and analysis.
The optical preclinical imaging market growth can also be accredited to the advent of new imaging technologies. Researchers have introduced imaging mass cytometry to analyze the detection of proteins within tissue sections with the help of heavy metal tagged antibodies. In September 2023, Revvity Inc., unveiled an enhanced imaging portfolio in preclinical research which includes IVIS® Spectrum 2 and the IVIS SpectrumCT 2 imaging systems, crafted to elevate the sensitivity standards in in vivo optical imaging.
To facilitate fast-tracking and rapid evaluation of therapeutic candidates, Revvity's QuantumTM GX3 microCT structural imaging solution has been enabled with increased resolution and speed for both in vivo and ex vivo imaging. Such product launches will add significant growth the optical preclinical imaging market value.
Global Optical Preclinical Imaging Market Segmentation
"Optical Preclinical Imaging Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:
Market Breakup by Modality
- Bioluminescence/Fluorescence Imaging Systems
- Standalone Fluorescence Imaging Systems
- Optical + X-Ray/ Optical + CT
- Bioluminescent Imaging Reagents
- Fluorescent Imaging Reagent
- Research and Development
- Drug Discovery
- Pharma and Biotech Companies
- Research Institutes
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
The United States is expected to lead the optical preclinical imaging market share with the implementation of the Inflation Reduction Act of 2022. This act emphasizes the reduction of device and drug prices in the country. This indicates that the traditional research and development methods will take a backseat as the pharma companies keenly adopt machine learning and artificial intelligence technology driven platforms to accelerate drug development. The integration has already been initiated and it is fairly smooth, owing to the presence of a robust healthcare infrastructure.
Europe has been one of the leading regions in the market as it is home to several academic institutions, pioneering research and development in numerous healthcare domains. Asia Pacific is also expected to witness the fastest growth attributed to rising medical infrastructure development. In addition, major healthcare companies have been making hefty investments in the region to leverage the easy availability of both economical and intellectual resources.
Global Optical Preclinical Imaging Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Stryker
- Smith+Nephew
- NuVasive Inc.
- Arthrex Inc.
- Orthofix US LLC
- Johnson & Johnson Services, Inc.
- Pega Medical Inc.
- WishBone Medical
- Zimmer Biomet
- Medtronic
- Auxein Medical
- Implanet SA
- Merete GmbH
- Mighty Oak Medical
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Optical Preclinical Imaging Market Overview
- 3.1 Global Optical Preclinical Imaging Market Historical Value (2018-2024)
- 3.2 Global Optical Preclinical Imaging Market Forecast Value (2025-2034)
- 4 Global Optical Preclinical Imaging Market Landscape
- 4.1 Global Optical Preclinical Imaging Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Optical Preclinical Imaging Product Landscape
- 4.2.1 Analysis by Modality
- 4.2.2 Analysis by Reagent
- 4.2.3 Analysis by Application
- 5 Global Optical Preclinical Imaging Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Optical Preclinical Imaging Market Segmentation
- 6.1 Global Optical Preclinical Imaging Market by Modality
- 6.1.1 Market Overview
- 6.1.2 Bioluminescence/Fluorescence Imaging Systems
- 6.1.3 Standalone Fluorescence Imaging Systems
- 6.1.4 Optical + X-Ray/ Optical + CT
- 6.2 Global Optical Preclinical Imaging Market by Reagent
- 6.2.1 Market Overview
- 6.2.2 Bioluminescent Imaging Reagents
- 6.2.3 Fluorescent Imaging Reagent
- 6.3 Global Optical Preclinical Imaging Market by Application
- 6.3.1 Market Overview
- 6.3.2 Research and Development
- 6.3.3 Drug Discovery
- 6.4 Global Optical Preclinical Imaging Market by End User
- 6.4.1 Market Overview
- 6.4.2 Pharma and Biotech Companies
- 6.4.3 Research Institutes
- 6.4.4 Others
- 6.5 Global Optical Preclinical Imaging Market by Region
- 6.5.1 Market Overview
- 6.5.2 North America
- 6.5.3 Europe
- 6.5.4 Asia Pacific
- 6.5.5 Latin America
- 6.5.6 Middle East and Africa
- 7 North America Optical Preclinical Imaging Market
- 7.1 Market Share by Country
- 7.2 United States of America
- 7.3 Canada
- 8 Europe Optical Preclinical Imaging Market
- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Optical Preclinical Imaging Market
- 9.1 Market Share by Country
- 9.2 China
- 9.3 Japan
- 9.4 India
- 9.5 ASEAN
- 9.6 Australia
- 9.7 Others
- 10 Latin America Optical Preclinical Imaging Market
- 10.1 Market Share by Country
- 10.2 Brazil
- 10.3 Argentina
- 10.4 Mexico
- 10.5 Others
- 11 Middle East and Africa Optical Preclinical Imaging Market
- 11.1 Market Share by Country
- 11.2 Saudi Arabia
- 11.3 United Arab Emirates
- 11.4 Nigeria
- 11.5 South Africa
- 11.6 Others
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Grants Analysis
- 13.1 Analysis by year
- 13.2 Analysis by Amount Awarded
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Grant Application
- 13.5 Analysis by Funding Institute
- 13.6 Analysis by NIH Departments
- 13.7 Analysis by Recipient Organization
- 14 Funding & Investment Analysis
- 14.1 Analysis by Funding Instances
- 14.2 Analysis by Type of Funding
- 14.3 Analysis by Funding Amount
- 14.4 Analysis by Leading Players
- 14.5 Analysis by Leading Investors
- 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
- 15.1 Analysis by Partnership Instances
- 15.2 Analysis by Type of Partnership
- 15.3 Analysis by Leading Players
- 15.4 Analysis by Geography
- 16 Supplier Landscape
- 16.1 Stryker
- 16.1.1 Financial Analysis
- 16.1.2 Product Portfolio
- 16.1.3 Demographic Reach and Achievements
- 16.1.4 Mergers and Acquisitions
- 16.1.5 Certifications
- 16.2 Smith+Nephew
- 16.2.1 Financial Analysis
- 16.2.2 Product Portfolio
- 16.2.3 Demographic Reach and Achievements
- 16.2.4 Mergers and Acquisitions
- 16.2.5 Certifications
- 16.3 NuVasive Inc.
- 16.3.1 Financial Analysis
- 16.3.2 Product Portfolio
- 16.3.3 Demographic Reach and Achievements
- 16.3.4 Mergers and Acquisitions
- 16.3.5 Certifications
- 16.4 Arthrex Inc.
- 16.4.1 Financial Analysis
- 16.4.2 Financial Portfolio
- 16.4.3 Demographic Reach and Achievements
- 16.4.4 Mergers and Acquisitions
- 16.4.5 Certifications
- 16.5 Orthofix US LLC
- 16.5.1 Financial Analysis
- 16.5.2 Product Portfolio
- 16.5.3 Demographic Reach and Achievements
- 16.5.4 Mergers and Acquisitions
- 16.5.5 Certifications
- 16.6 Johnson & Johnson Services, Inc.
- 16.6.1 Financial Analysis
- 16.6.2 Product Portfolio
- 16.6.3 Demographic Reach and Achievements
- 16.6.4 Mergers and Acquisitions
- 16.6.5 Certifications
- 16.7 Pega Medical Inc.
- 16.7.1 Financial Analysis
- 16.7.2 Product Portfolio
- 16.7.3 Demographic Reach and Achievements
- 16.7.4 Mergers and Acquisitions
- 16.7.5 Certifications
- 16.8 WishBone Medical
- 16.8.1 Financial Analysis
- 16.8.2 Product Portfolio
- 16.8.3 Demographic Reach and Achievements
- 16.8.4 Mergers and Acquisitions
- 16.8.5 Certifications
- 16.9 Zimmer Biomet
- 16.9.1 Financial Analysis
- 16.9.2 Product Portfolio
- 16.9.3 Demographic Reach and Achievements
- 16.9.4 Mergers and Acquisitions
- 16.9.5 Certifications
- 16.10 Medtronic
- 16.10.1 Financial Analysis
- 16.10.2 Product Portfolio
- 16.10.3 Demographic Reach and Achievements
- 16.10.4 Mergers and Acquisitions
- 16.10.5 Certifications
- 16.11 Auxein Medical
- 16.11.1 Financial Analysis
- 16.11.2 Product Portfolio
- 16.11.3 Demographic Reach and Achievements
- 16.11.4 Mergers and Acquisitions
- 16.11.5 Certifications
- 16.12 Implanet SA
- 16.12.1 Financial Analysis
- 16.12.2 Product Portfolio
- 16.12.3 Demographic Reach and Achievements
- 16.12.4 Mergers and Acquisitions
- 16.12.5 Certifications
- 16.13 Merete GmbH
- 16.13.1 Financial Analysis
- 16.13.2 Product Portfolio
- 16.13.3 Demographic Reach and Achievements
- 16.13.4 Mergers and Acquisitions
- 16.13.5 Certifications
- 16.14 Mighty Oak Medical
- 16.14.1 Financial Analysis
- 16.14.2 Product Portfolio
- 16.14.3 Demographic Reach and Achievements
- 16.14.4 Mergers and Acquisitions
- 16.14.5 Certifications
- 17 Global Optical Preclinical Imaging Market - Distribution Model (Additional Insight)
- 17.1 Overview
- 17.2 Potential Distributors
- 17.3 Key Parameters for Distribution Partner Assessment
- 18 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 19 Company Competitiveness Analysis (Additional Insight)
- 19.1 Very Small Companies
- 19.2 Small Companies
- 19.3 Mid-Sized Companies
- 19.4 Large Companies
- 19.5 Very Large Companies
- 20 Payment Methods (Additional Insight)
- 20.1 Government Funded
- 20.2 Private Insurance
- 20.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.